Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906457 | 0.94 | — | — | |
| SCHEMBL28198552 | 0.86 | ALDH1A1 (0.31) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL22661231 | 0.86 | MEN1 (0.32) | ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL11279952 | 0.85 | MEN1 (0.31) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8596835 | 0.84 | HSD17B10 (0.31) | ALDH1A1HSD17B10 | |
| SCHEMBL9976316 | 0.84 | LMNA (0.46) | LMNA | |
| SCHEMBL9009185 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9787585 | 0.76 | KDM4E (0.31) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL30663537 | 0.73 | LMNA (0.41) | LMNA | |
| SCHEMBL11278009 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354842-A | Improved preparation method of iomeprol and application of iomeprol in preparation | 重庆圣华曦药业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3580199-B1 | METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS | GUERBET SA (FR) | 2023-04-05 | — | — | EP | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221189-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| US-4352788-A | ARTERIES | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | TPO, NISCH, PPIP5K2 | ALDH1A1 2138/4885LMNA 3525/4885HSD17B10 2776/4885 |
| US-20100221189-A1 | CONTRAST AGENTS | NR1I3, NR1I2, NR1D2 | ALDH1A1 1588/4885LMNA 2753/4885HSD17B10 1215/4885 |
| US-20100233097-A1 | CONTRAST AGENTS | C1R, C3AR1, CNKSR1 | ALDH1A1 2310/4885LMNA 1939/4885HSD17B10 2016/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | ALDH1A1 2186/4885LMNA 2025/4885HSD17B10 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.